BIOTECH PHARMACEUTICAL CO., LTD
BIOTECH PHARMACEUTICAL CO., LTD (abbreviated as “BPL”), was founded in 2000. BPL is an early national high-tech enterprise engaged in the R&D, manufacturing and sales of innovative biological drugs such as monoclonal antibody and therapeutic vaccines.
BPL is an important strategic cooperation project between China and Cuba in the biopharmaceutical field. Nimotuzumab injection (Trade name: Taixinsheng®), BPL's self-developed new Class I biological drug and China’s first monoclonal antibody drug for the treatment of malignant tumors, has been on the Chinese market for more than 10 years. It was included in NCCN Clinical Practice Guidelines in Oncology (2010), as well as in the catalog of medicines covered by the Chinese national basic medical insurance in 2017. Several clinical studies for registration of Nimotuzumab are underway to expand its approved indications, which will benefit more patients with cancer and improve their survival benefits.
Nimotuzumab (trade name: Taixinsheng®) is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR) for the treatment of malignant tumors. It was marketed in China in 2008 and has been included in NCCN Clinical Practice Guidelines in Oncology. It is, for the moment, the only macromolecular targeted drug used for first-line treatment of nasopharyngeal carcinoma in China. Due to its significant efficacy and safety, it was included in the catalog of medicines covered by the Chinese national basic medical insurance in 2017 to benefit more patients with cancer. At present, several clinical studies for registration of Nimotuzumab in treating esophageal cancer, pancreatic cancer and cervical cancer are ongoing, providing evidence-based medical proofs for more indications.
EGF vaccine (rEGF-p64K/Mont vaccine) is a chemically conjugated peptide vaccine jointly developed by Biotech Pharmaceutical Co., Ltd. and Cuba. It is a conjugate of recombinant human epidermal growth factor (hu-rEGF) generated in brewer's yeast and recombinant Neisseria meningitidis P64k protein generated in escherichia coli.